Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor

Syuntaro Takasu, Toshitada Takahashi, Sho Okamoto, Noboru Oriuchi, Norihisa Nakayashiki, Kenta Okamoto, Hideki Muramatsu, Takeshi Hayashi, Norimoto Nakahara, Masaaki Mizuno, Toshihiko Wakabayashi, Tetsuya Higuchi, Keigo Endo, Kenichi Kozaki, Osamu Miyaishi, Shinsuke Saga, Ryuzo Ueda, Jun Yoshida, Kazuhiro Yoshikawa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The type III mutant epidermal growth factor receptor (EGFR) is expressed on the cell surface of a subset of glioma, but not of normal tissues. In this study, we investigated the in vivo kinetics of 3C10 mouse monoclonal antibody (mAb), specifically recognizing the type III mutant EGFR (EGFRvIII), using athymic nude mice bearing the intracranial glioma xenograft overexpressing the EGFRvIII. Human glioma cell line, U87MG, expressing the wild type EGFR and the transfectant, named U87MG·ΔEGFR, expressing the EGFRvIII, were transplanted subcutaneously or intracranially to nude mice. 3C10 mAb labeled with a technetium-99m (99mTc) was intravenously injected into these nude mice and then the mice were sacrificed at 24 h later, and the 99mTc-uptake by xenografts and major normal organs was measured to determine the biodistribution of mAb. Furthermore, at 3, 6 and 24 h after injection of 99mTc-labeled 3C10 mAb, whole-body scintigraphy was obtained with a gamma camera to localize the tumor site. 3C10 mAb significantly accumulated to U87MG·ΔEGFR xenografts transplanted subcutaneously or intracranially in nude mice, showing high tumor-to-blood ratio of 10.30 and 4.01, respectively. In contrast, uptake of control antibody in the intracranial tumor was as low as 0.43. In scintigrams, intracranially transplanted U87MG·ΔEGFR xenografts were detectable at 3 h after injection of 99mTc-labeled 3C10 mAb. These results suggest that intravenously injected 3C10 mAb specifically accumulated to the subcutaneous or intracranial glioma xenograft expressing the EGFRvIII and 3C10 mAb is a potential diagnostic and therapeutic agent for patients with gliomas expressing the EGFRvIII.

Original languageEnglish
Pages (from-to)247-256
Number of pages10
JournalJournal of Neuro-Oncology
Volume63
Issue number3
DOIs
Publication statusPublished - Jul 2003
Externally publishedYes

Fingerprint

Radioimmunodetection
Technetium
Epidermal Growth Factor Receptor
Heterografts
Glioma
Monoclonal Antibodies
Nude Mice
Neoplasms
Injections
Gamma Cameras
Proxy
Radionuclide Imaging
epidermal growth factor receptor VIII
Cell Line
Antibodies

Keywords

  • 99mTc
  • Biodistribution
  • EGFRvIII
  • Monoclonal antibody
  • Radioimmunoscientigraphy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. / Takasu, Syuntaro; Takahashi, Toshitada; Okamoto, Sho; Oriuchi, Noboru; Nakayashiki, Norihisa; Okamoto, Kenta; Muramatsu, Hideki; Hayashi, Takeshi; Nakahara, Norimoto; Mizuno, Masaaki; Wakabayashi, Toshihiko; Higuchi, Tetsuya; Endo, Keigo; Kozaki, Kenichi; Miyaishi, Osamu; Saga, Shinsuke; Ueda, Ryuzo; Yoshida, Jun; Yoshikawa, Kazuhiro.

In: Journal of Neuro-Oncology, Vol. 63, No. 3, 07.2003, p. 247-256.

Research output: Contribution to journalArticle

Takasu, S, Takahashi, T, Okamoto, S, Oriuchi, N, Nakayashiki, N, Okamoto, K, Muramatsu, H, Hayashi, T, Nakahara, N, Mizuno, M, Wakabayashi, T, Higuchi, T, Endo, K, Kozaki, K, Miyaishi, O, Saga, S, Ueda, R, Yoshida, J & Yoshikawa, K 2003, 'Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor', Journal of Neuro-Oncology, vol. 63, no. 3, pp. 247-256. https://doi.org/10.1023/A:1024320516341
Takasu, Syuntaro ; Takahashi, Toshitada ; Okamoto, Sho ; Oriuchi, Noboru ; Nakayashiki, Norihisa ; Okamoto, Kenta ; Muramatsu, Hideki ; Hayashi, Takeshi ; Nakahara, Norimoto ; Mizuno, Masaaki ; Wakabayashi, Toshihiko ; Higuchi, Tetsuya ; Endo, Keigo ; Kozaki, Kenichi ; Miyaishi, Osamu ; Saga, Shinsuke ; Ueda, Ryuzo ; Yoshida, Jun ; Yoshikawa, Kazuhiro. / Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. In: Journal of Neuro-Oncology. 2003 ; Vol. 63, No. 3. pp. 247-256.
@article{69b7fe2e439b462fa07602366dc6884a,
title = "Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor",
abstract = "The type III mutant epidermal growth factor receptor (EGFR) is expressed on the cell surface of a subset of glioma, but not of normal tissues. In this study, we investigated the in vivo kinetics of 3C10 mouse monoclonal antibody (mAb), specifically recognizing the type III mutant EGFR (EGFRvIII), using athymic nude mice bearing the intracranial glioma xenograft overexpressing the EGFRvIII. Human glioma cell line, U87MG, expressing the wild type EGFR and the transfectant, named U87MG·ΔEGFR, expressing the EGFRvIII, were transplanted subcutaneously or intracranially to nude mice. 3C10 mAb labeled with a technetium-99m (99mTc) was intravenously injected into these nude mice and then the mice were sacrificed at 24 h later, and the 99mTc-uptake by xenografts and major normal organs was measured to determine the biodistribution of mAb. Furthermore, at 3, 6 and 24 h after injection of 99mTc-labeled 3C10 mAb, whole-body scintigraphy was obtained with a gamma camera to localize the tumor site. 3C10 mAb significantly accumulated to U87MG·ΔEGFR xenografts transplanted subcutaneously or intracranially in nude mice, showing high tumor-to-blood ratio of 10.30 and 4.01, respectively. In contrast, uptake of control antibody in the intracranial tumor was as low as 0.43. In scintigrams, intracranially transplanted U87MG·ΔEGFR xenografts were detectable at 3 h after injection of 99mTc-labeled 3C10 mAb. These results suggest that intravenously injected 3C10 mAb specifically accumulated to the subcutaneous or intracranial glioma xenograft expressing the EGFRvIII and 3C10 mAb is a potential diagnostic and therapeutic agent for patients with gliomas expressing the EGFRvIII.",
keywords = "99mTc, Biodistribution, EGFRvIII, Monoclonal antibody, Radioimmunoscientigraphy",
author = "Syuntaro Takasu and Toshitada Takahashi and Sho Okamoto and Noboru Oriuchi and Norihisa Nakayashiki and Kenta Okamoto and Hideki Muramatsu and Takeshi Hayashi and Norimoto Nakahara and Masaaki Mizuno and Toshihiko Wakabayashi and Tetsuya Higuchi and Keigo Endo and Kenichi Kozaki and Osamu Miyaishi and Shinsuke Saga and Ryuzo Ueda and Jun Yoshida and Kazuhiro Yoshikawa",
year = "2003",
month = "7",
doi = "10.1023/A:1024320516341",
language = "English",
volume = "63",
pages = "247--256",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor

AU - Takasu, Syuntaro

AU - Takahashi, Toshitada

AU - Okamoto, Sho

AU - Oriuchi, Noboru

AU - Nakayashiki, Norihisa

AU - Okamoto, Kenta

AU - Muramatsu, Hideki

AU - Hayashi, Takeshi

AU - Nakahara, Norimoto

AU - Mizuno, Masaaki

AU - Wakabayashi, Toshihiko

AU - Higuchi, Tetsuya

AU - Endo, Keigo

AU - Kozaki, Kenichi

AU - Miyaishi, Osamu

AU - Saga, Shinsuke

AU - Ueda, Ryuzo

AU - Yoshida, Jun

AU - Yoshikawa, Kazuhiro

PY - 2003/7

Y1 - 2003/7

N2 - The type III mutant epidermal growth factor receptor (EGFR) is expressed on the cell surface of a subset of glioma, but not of normal tissues. In this study, we investigated the in vivo kinetics of 3C10 mouse monoclonal antibody (mAb), specifically recognizing the type III mutant EGFR (EGFRvIII), using athymic nude mice bearing the intracranial glioma xenograft overexpressing the EGFRvIII. Human glioma cell line, U87MG, expressing the wild type EGFR and the transfectant, named U87MG·ΔEGFR, expressing the EGFRvIII, were transplanted subcutaneously or intracranially to nude mice. 3C10 mAb labeled with a technetium-99m (99mTc) was intravenously injected into these nude mice and then the mice were sacrificed at 24 h later, and the 99mTc-uptake by xenografts and major normal organs was measured to determine the biodistribution of mAb. Furthermore, at 3, 6 and 24 h after injection of 99mTc-labeled 3C10 mAb, whole-body scintigraphy was obtained with a gamma camera to localize the tumor site. 3C10 mAb significantly accumulated to U87MG·ΔEGFR xenografts transplanted subcutaneously or intracranially in nude mice, showing high tumor-to-blood ratio of 10.30 and 4.01, respectively. In contrast, uptake of control antibody in the intracranial tumor was as low as 0.43. In scintigrams, intracranially transplanted U87MG·ΔEGFR xenografts were detectable at 3 h after injection of 99mTc-labeled 3C10 mAb. These results suggest that intravenously injected 3C10 mAb specifically accumulated to the subcutaneous or intracranial glioma xenograft expressing the EGFRvIII and 3C10 mAb is a potential diagnostic and therapeutic agent for patients with gliomas expressing the EGFRvIII.

AB - The type III mutant epidermal growth factor receptor (EGFR) is expressed on the cell surface of a subset of glioma, but not of normal tissues. In this study, we investigated the in vivo kinetics of 3C10 mouse monoclonal antibody (mAb), specifically recognizing the type III mutant EGFR (EGFRvIII), using athymic nude mice bearing the intracranial glioma xenograft overexpressing the EGFRvIII. Human glioma cell line, U87MG, expressing the wild type EGFR and the transfectant, named U87MG·ΔEGFR, expressing the EGFRvIII, were transplanted subcutaneously or intracranially to nude mice. 3C10 mAb labeled with a technetium-99m (99mTc) was intravenously injected into these nude mice and then the mice were sacrificed at 24 h later, and the 99mTc-uptake by xenografts and major normal organs was measured to determine the biodistribution of mAb. Furthermore, at 3, 6 and 24 h after injection of 99mTc-labeled 3C10 mAb, whole-body scintigraphy was obtained with a gamma camera to localize the tumor site. 3C10 mAb significantly accumulated to U87MG·ΔEGFR xenografts transplanted subcutaneously or intracranially in nude mice, showing high tumor-to-blood ratio of 10.30 and 4.01, respectively. In contrast, uptake of control antibody in the intracranial tumor was as low as 0.43. In scintigrams, intracranially transplanted U87MG·ΔEGFR xenografts were detectable at 3 h after injection of 99mTc-labeled 3C10 mAb. These results suggest that intravenously injected 3C10 mAb specifically accumulated to the subcutaneous or intracranial glioma xenograft expressing the EGFRvIII and 3C10 mAb is a potential diagnostic and therapeutic agent for patients with gliomas expressing the EGFRvIII.

KW - 99mTc

KW - Biodistribution

KW - EGFRvIII

KW - Monoclonal antibody

KW - Radioimmunoscientigraphy

UR - http://www.scopus.com/inward/record.url?scp=0038298286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038298286&partnerID=8YFLogxK

U2 - 10.1023/A:1024320516341

DO - 10.1023/A:1024320516341

M3 - Article

C2 - 12892230

AN - SCOPUS:0038298286

VL - 63

SP - 247

EP - 256

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -